Mather Group’s Takeda Pharmaceutical TAK Stock Holding History

Mather Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04K	Hold	65	–	–	﹤0.01%	1796
2026 Q1	$1.2K	Buy	+65	New	+$1.14K	﹤0.01%	1757
2025 Q4	–	Sell	-104	Closed	-$1.52K	–	1538
2025 Q3	$1.52K	Buy	+104	New	+$1.54K	﹤0.01%	1560
2025 Q2	–	Sell	-104	Closed	-$1.55K	–	1602
2025 Q1	$1.55K	Sell	104 -1	-1%	-$14	﹤0.01%	1597
2024 Q4	$1.39K	Sell	105 -8	-7%	-$110	﹤0.01%	1580
2024 Q3	$1.61K	Buy	113 +109	+2,725%	+$1.55K	﹤0.01%	1511
2024 Q2	$56	Sell	4 -29	-88%	-$384	﹤0.01%	2163
2024 Q1	$471	Buy	+33	New	+$480	﹤0.01%	1687

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Mather Group's TAK Position: Q2 2026 in Review

Mather Group held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 65 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #1796.

Mather Group first reported a position in TAK in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.61K in Q3 2024. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Mather Group held 65 shares of Takeda Pharmaceutical worth $1.04K as of Q2 2026.
Mather Group left its Takeda Pharmaceutical share count unchanged in Q2 2026.
Takeda Pharmaceutical made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1796 holding.
Mather Group first reported a position in Takeda Pharmaceutical in Q1 2024 and has held it in 8 quarters since.
Mather Group's Takeda Pharmaceutical position peaked at $1.61K in Q3 2024.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.